| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 05/24/2000 | EP1002533A1 Use of chromanes and/or chromenes derivatives to prevent oxidative reactions induced by free radicals |
| 05/24/2000 | EP1002530A2 Delivery systems for active ingredients comprising a salicylic acid derivative composition on a film structure and their use |
| 05/24/2000 | EP1002526A1 Skin whitening composition containing bearberry extract and a reducing agent |
| 05/24/2000 | EP1002525A2 N-acylate derivatives of pyrrolidone carboxylic acid as surfactant |
| 05/24/2000 | EP1002069A1 Peptides containing the motif igd and their use as cell migration modulators |
| 05/24/2000 | EP1002064A1 A modified polypeptide |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001955A1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001946A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES |
| 05/24/2000 | EP1001945A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES |
| 05/24/2000 | EP1001792A1 Use of physiologically acceptable vanadium compounds, salts and complexes |
| 05/24/2000 | EP1001785A1 Use of colchinol derivatives as vascular damaging agents |
| 05/24/2000 | EP1001770A1 Tazarotene and uvb phototherapy treatment for psoriasis |
| 05/24/2000 | EP1001766A1 Compounds and methods |
| 05/24/2000 | EP1001759A2 Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001753A1 Low dosed 15-desoxyspergualine preparations |
| 05/24/2000 | EP1001741A1 Use of amino phenol amide derivatives as depigmentation agents |
| 05/24/2000 | EP1001740A1 USE OF THE Rb 1? GINSENOSIDE FOR STIMULATING ELASTIN SYNTHESIS |
| 05/24/2000 | EP1001739A1 Use of a 2-amino-alkane polyol as agent for treating skin ageing signs |
| 05/24/2000 | EP1001677A1 A novel method for treating epidermal or dermal conditions |
| 05/24/2000 | EP0626969B1 CoA-IT AND PAF INHIBITORS |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1253825A Moistening ointment for curing burn |
| 05/24/2000 | CN1253820A Chinese medicine crust-eliminating non-scaring ointment for external application for curing burn |
| 05/24/2000 | CN1253814A Medicine for curing burn |
| 05/24/2000 | CN1253812A Shaotangning medicine for curing burn and scald and its preparation method |
| 05/24/2000 | CN1253805A Fenciling capsule for curing comedo |
| 05/24/2000 | CN1253780A Method for extracting active component of sea cockroach |
| 05/24/2000 | CN1253768A Application of cholesteryl liquid crystal polymer as ultraviolet shielding agent in cosmetics and medicine preparation |
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066676 Pharmaceutical composition and methods for using it |
| 05/23/2000 | US6066663 Oxidation derivatives of indolylalkylamines and their use as drugs |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066328 Cosmetic or dermatological composition comprising an oil-in-water emulsion comprising oily globules with a lamellar liquid crystal coating |
| 05/23/2000 | US6066327 Antioxidant mixture |
| 05/18/2000 | WO2000028035A1 CHEMOKINE β-7 |
| 05/18/2000 | WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027820A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027429A2 Vaccine against papillomatous digital dermatitis (pdd) |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027395A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | WO2000027356A1 Self-foaming cleansing systems |
| 05/18/2000 | WO2000027352A1 Topical compositions containing whey proteins |
| 05/18/2000 | WO2000027351A1 Use of at least a genus ocimum plant extract |
| 05/18/2000 | WO2000027327A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| 05/18/2000 | WO2000027207A1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 05/18/2000 | WO2000009130A3 New pharmaceutical uses for nos inhibitors |
| 05/18/2000 | WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase |
| 05/18/2000 | WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 05/18/2000 | WO1999024470A8 Mammalian milk growth factor |
| 05/18/2000 | DE19945814A1 Verfahren zur Zubereitung eines pharmazeutischen Artemisia-Extraktes und Vorrichtung zur elektrischen Moxibustion unter Verwendung des Extraktes A process for the preparation of a pharmaceutical Artemisia extract and moxibustion device for electrically using the extract |
| 05/18/2000 | DE19852508A1 Use of fat-soluble substance obtained from avocado oil as an antiphlogistic, antirheumatic, antimycotic or antiscabiotic agent, or as a toothpaste, lipstick, leather treatment agent or in bandages |
| 05/18/2000 | DE19852245A1 5-Aminolävulinsäure-Nanoemulsion 5-aminolevulinic acid nanoemulsions |
| 05/18/2000 | DE19848260A1 Fumarsäure-Mikrotabletten Fumaric microtablets |
| 05/18/2000 | CA2351145A1 Vaccine against papillomatous digital dermatitis (pdd) |
| 05/18/2000 | CA2350771A1 Chemokine .beta.-7 |
| 05/18/2000 | CA2350628A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2350211A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | CA2350182A1 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | CA2348946A1 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2346898A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 05/18/2000 | CA2317049A1 Topical compositions containing whey proteins |
| 05/17/2000 | EP1000618A1 Topical capsaicin preparation |
| 05/17/2000 | EP1000542A1 Antimicrobial composition and its use, especially in cosmetics and dermatology |
| 05/17/2000 | EP1000166A2 Inhibitors of cell-cycle progression and uses related thereto |
| 05/17/2000 | EP1000089A1 Collagen type i and type iii adhesive compositions |
| 05/17/2000 | EP1000055A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP1000040A1 Il-5 inhibiting 6-azauracil derivatives |
| 05/17/2000 | EP1000035A1 Substituted 6-phenylphenanthridines |
| 05/17/2000 | EP1000034A1 Substituted 6-alkylphenanthridines |
| 05/17/2000 | EP1000031A1 Vitronectin receptor antagonist |
| 05/17/2000 | EP1000017A1 Il-8 receptor antagonists |
| 05/17/2000 | EP0999846A1 Phosphatidic acid-based immune modulator composition |
| 05/17/2000 | EP0999842A1 Novel substituted imidazole compounds |
| 05/17/2000 | EP0796238B1 Method of stabilizing polyunsaturated fatty acids and their application in therapy and cosmetics |
| 05/17/2000 | EP0689426B1 Therapeutic agent for the treatment of melanomas |
| 05/17/2000 | EP0644764B1 Lipids for epidermal moisturization and repair of barrier function |
| 05/17/2000 | EP0615545B1 Lysates derived from keratinocytes for use as wound healing substances |
| 05/17/2000 | CN1253560A Sulfonamides for treatment of endothelin-mediated disorders |
| 05/17/2000 | CN1253559A Sulfonyl divalent aryl alpha-hydroxamic acid compounds |
| 05/17/2000 | CN1253504A Cytokine related treatments of disease |
| 05/17/2000 | CN1253501A IL-8 receptor antagonists |